Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Sun Yat-sen University is the lead sponsor of 490 current clinical trials in our China register. 305 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Cisplatin, Toripalimab and Gemcitabine. The most-studied condition is Nasopharyngeal Carcinoma.

ClinicalTrials.gov trials by status

Recruiting30562%
Not yet open10121%
Active, closed7616%
By invitation82%

Trials by phase

Phase 220943%
Phase 39519%
Not applicable7716%
Observational6814%
Phase 1/2163%
Phase 1112%
Phase 2/3102%
Phase 420%
Phase EARLY_PHASE120%

Clinical trials sponsored by Sun Yat-sen University

490 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer NCT07086456 · Surufatinib, Tislelizumab, Concurrent Chemoradiotherapy Drugs: Surufatinib, Tislelizumab	Phase 2	Recruiting	2025-07	China
Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma NCT06793956 · Extranodal Natural Killer/T Cell Lymphoma	Phase 1	Recruiting	2025-02	China
The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer NCT05984485 · Rectal Cancer	Phase 3	Recruiting	2022-07	China
Clinical Study on the Safety, Efficacy and Pharmacokinetics of Telpegfilgrastim in Pediatric Cancer Patients with Chemotherapy NCT06857292 · ClinicalTrials.gov ↗ · Chemotherapy-Induced Neutropenia Drug: Telpegfilgrastim	Phase 2	Recruiting	2024-12	China
A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC) NCT06829147 · ClinicalTrials.gov ↗ · Nasopharyngeal Cancinoma (NPC), Lymph Node Metastasis	Observational	Recruiting	2024-11	China
Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer NCT06877416 · ClinicalTrials.gov ↗ · Antibody-drug Conjugates, HER2-low Breast Cancer, Breast Neoplasms	Observational	Recruiting	2020-01	China
PaCIFiC-CUP Classifies Cancer of Unknown Primary NCT06140992 · ClinicalTrials.gov ↗ · Unknown Primary Tumors, DNA Methylation	Observational	Recruiting	2023-07	China
Clinical Study of Radical Right Hemicolectomy Versus Radical Right Hemicolectomy Combined with Indocyanine Green Fluorescence Imaging Lymphatic Tracer Dissection for the Treatment of Right Colon Cancer NCT06485609 · ClinicalTrials.gov ↗ · Colon Cancer	Not applicable	Recruiting	2024-08	China
Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC NCT07052669 · ClinicalTrials.gov ↗ · Locally Advanced Non-Small Cell Lung Cancer	Phase 3	Recruiting	2025-07	China
Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy NCT05965531 · ClinicalTrials.gov ↗ · Rectal Cancer Drug: Trifluridine/Tipiracil	Phase 2	Recruiting	2024-01	China
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. NCT06563999 · ClinicalTrials.gov ↗ · Lung Cancer Stage III, Mutation Drugs: Crizotinib, Dabrafenib, Ensartinib	Phase 2	Recruiting	2024-11	China
Adebrelimab and Chemoradiotherapy in High-risk LANPC NCT06349889 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Nasopharyngeal Cancer Drug: Adebrelimab	Phase 2	Recruiting	2024-07	China
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer NCT06764680 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic, Chemotherapy, Targeted Therapy Drug: Bevacizumab	Phase 2	Recruiting	2024-12	China
Evaluation of COVID-19 Immune Barrier and Reinfection Risk NCT05774093 · ClinicalTrials.gov ↗ · COVID-19 Infection, Immunization; Infection	Observational	Recruiting	2023-03	China
Aortic Valve Diseases RISk facTOr assessmenT and Prognosis modeL Construction NCT06069232 · ClinicalTrials.gov ↗ · Aortic Valve Disease	Observational	Recruiting	2021-03	China
2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma NCT06492460 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck	Phase 3	Recruiting	2024-09	China
BAI-BACE for Advanced Lung Squamous Cell Carcinoma NCT06377735 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma	Not applicable	Recruiting	2024-05	China
Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer NCT06520683 · ClinicalTrials.gov ↗ · Colorectal Cancer, Microsatellite Instability High Drug: Tislelizumab	Phase 3	Recruiting	2024-11	China
Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer NCT07448142 · ClinicalTrials.gov ↗ · Colorectal Cancer (CRC) Drugs: CAPEOX/XELOX, Pucotenlimab	Phase 2	Recruiting	2026-03	China
Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening NCT05447169 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Observational	Recruiting	2022-07	China
Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma NCT07661771 · ClinicalTrials.gov ↗ · Non-metastatic Nasopharyngeal Carcinoma	Phase 3	Recruiting	2026-07	China
Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen NCT06456892 · ClinicalTrials.gov ↗ · Rhabdomyosarcoma, Pediatric Cancer Drug: Pucotenlimab	Phase 1/2	Recruiting	2024-06	China
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL) NCT04989621 · ClinicalTrials.gov ↗ · Follicular Lymphoma, Relapsed and Refractory Follicular Lymphoma	Phase 2	Recruiting	2021-08	China
Epstein-Barr Virus and Cancer Risks NCT06203314 · ClinicalTrials.gov ↗ · Cancer	Observational	Recruiting	2008-08	China
Prebiotics and the Management of Hyperuricemia NCT06420401 · ClinicalTrials.gov ↗ · Subjects With Hyperuricemia	Not applicable	Recruiting	2024-05	China
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma NCT06455410 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma Drugs: Adebrelimab, CCRT, Concurrent chemoradiotherapy	Phase 2	Recruiting	2024-06	China
Umbilical Cord Blood NK Cell Therapy for High-Risk Pediatric Soft Tissue Sarcoma: Efficacy and Safety Study NCT06848582 · ClinicalTrials.gov ↗ · Soft Tissue Sarcoma (STS)	Not applicable	Recruiting	2024-11	China
Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL NCT07494565 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma (DLBCL), CD5 Positive Drugs: Celecoxib, R-Chop	Phase 2	Recruiting	2026-03	China
The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy. NCT06019455 · ClinicalTrials.gov ↗ · Lung Cancer, Esophageal Cancer	Observational	Recruiting	2022-06	China
Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma NCT06611150 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC) Drug: Nab-paclitaxel	Phase 1	Recruiting	2024-08	China
Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma NCT05080010 · ClinicalTrials.gov ↗ · Retinoblastoma	Phase 3	Recruiting	2020-11	China
Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment NCT07238881 · ClinicalTrials.gov ↗ · Hepatocellulcar Carcinoma Drugs: Camrelizumab, Dalpiciclib Isetionate	Phase 2	Recruiting	2025-11	China
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer NCT06441565 · ClinicalTrials.gov ↗ · Colorectal Cancer Drugs: Fluorouracil, Fruquintinib, Oxaliplatin	Phase 2/3	Recruiting	2024-05	China
Comparison of Posterior Continuous Curvilinear Capsulorhexis With or Without Anterior Vitrectomy NCT05136209 · ClinicalTrials.gov ↗ · Congenital Cataract	Not applicable	Recruiting	2021-11	China
Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study NCT07583511 · ClinicalTrials.gov ↗ · Small-cell Lung Cancer Drugs: Cisplatin, Etoposide, Serplulimab	Phase 2	Recruiting	2024-02	China
TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT NCT06622031 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Systemic Therapy Drug: Lenvatinib	Not applicable	Recruiting	2024-10	China
TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma NCT06301165 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Recruiting	2024-03	China
Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma NCT07516678 · ClinicalTrials.gov ↗ · Neuroblastoma	Observational	Recruiting	2022-01	China
PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC NCT06977074 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC)	Phase 2	Recruiting	2025-05	China
De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma NCT06313450 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Radiotherapy; Complications, IMMUNOTHERAPY	Not applicable	Recruiting	2024-03	China
A Phase II Clinical Trial of Artificial Intelligence-assisted One-stop Radiotherapy for Breast Cancer After Breast-conserving Surgery NCT06686459 · ClinicalTrials.gov ↗ · Breast Cancer Invasive	Not applicable	Recruiting	2025-04	China
Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors NCT07258108 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	2025-11	China
Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC NCT06467799 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Beyond Milan Criteria	Phase 2	Recruiting	2024-09	China
Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma NCT04448522 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Radiotherapy, Chemotherapy	Phase 3	Recruiting	2020-08	China
Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in Children NCT07188311 · ClinicalTrials.gov ↗ · Hepatoblastoma, Pediatric Cancer	Not applicable	Recruiting	2025-04	China
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma NCT06333561 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Lenvatinib, PD-1 Inhibitor	Observational	Recruiting	2021-01	China
Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer NCT05959356 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	2023-11	China
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients NCT06280495 · ClinicalTrials.gov ↗ · Colorectal Cancer, Liver Metastases Drugs: Bevacizumab, Fluorouracil, Ivonescimab	Phase 2/3	Recruiting	2024-02	China
Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial NCT07622771 · ClinicalTrials.gov ↗ · Rectal Cancers	Phase 2	Recruiting	2026-05	China
Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) NCT06187597 · ClinicalTrials.gov ↗ · Locally Advanced Esophageal Squamous Cell Carcinoma Drugs: Tegafur Gimeracil Oteracil, Toripalimab	Phase 2	Recruiting	2024-03	China
Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma NCT06730308 · ClinicalTrials.gov ↗ · Thymoma Drug: Methylprednisolone	Phase 2	Recruiting	2024-11	China
A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) NCT06241599 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Nasopharyngeal Carcinoma	Phase 2/3	Recruiting	2024-02	China
A Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and Monitoring the Recurrence and Metastasis of Hepatoblastoma in Children and Adolescents NCT07300449 · ClinicalTrials.gov ↗ · Hepatoblastoma	Phase 2	Recruiting	2021-06	China
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Centrally Located Early-stage Non-small Cell Lung Cancer NCT06730295 · ClinicalTrials.gov ↗ · Lung Cancer (NSCLC)	Phase 2	Recruiting	2024-12	China
Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma NCT06630780 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma (HNSCC)	Not applicable	Recruiting	2024-09	China
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma NCT05342792 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma Drugs: Capecitabine, Tislelizumab	Phase 3	Recruiting	2022-04	China
Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors NCT06015802 · ClinicalTrials.gov ↗ · Pituitary Adenoma, Neuroendocrine Tumors	Observational	Recruiting	2021-04	China
Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma. NCT06533267 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Intensity Modulated Radiotherapy, Surgery	Not applicable	Recruiting	2024-03	China
JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma NCT05173246 · ClinicalTrials.gov ↗ · Esophageal Small Cell Carcinoma	Phase 2	Recruiting	2020-11	China
Postoperative Hypoxemia Increases the Risk of Anastomotic Leak After Radical Esophagectomy NCT07309991 · ClinicalTrials.gov ↗ · Esophageal Carcinoma, Esophageal Adenocarcinoma, Esophagectomy	Observational	Recruiting	2021-01	China
WHO Mental Health Gap Action Program (mhGAP) for Improving Child Mental and Behavioral Disorder Service Quality in China NCT06702410 · ClinicalTrials.gov ↗ · Neurodevelopmental Disorders	Not applicable	Recruiting	2024-11	China
An AI Educational Agent for Medical Machine Learning Courses NCT07449182 · ClinicalTrials.gov ↗ · Medical Education, Artificial Intelligence in Medicine	Not applicable	Recruiting	2025-05	China
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC NCT06609876 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Microwave Ablation, Donafenib Drug: Donafenib	Not applicable	Recruiting	2024-10	China
Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer NCT06903858 · ClinicalTrials.gov ↗ · Colorectal Cancer, Microsatellite Instability High, Mismatch Repair Deficiency Drugs: Celecoxib, Toripalimab	Phase 2	Recruiting	2025-06	China
Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases NCT05794971 · ClinicalTrials.gov ↗ · Colorectal Cancer Liver Metastases, Regorafenib Drug: Regorafenib	Phase 3	Recruiting	2023-06	China
Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma. NCT06631391 · ClinicalTrials.gov ↗ · Neuroblastoma	Phase 1	Recruiting	2024-11	China
Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis NCT06582940 · ClinicalTrials.gov ↗ · MRI-guided Adaptive Radiotherapy, Non-small Cell Lung Cancer, Brain Metastasis	Phase 2	Recruiting	2024-03	China
Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study NCT06547203 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic Drugs: Cetuximab, Irinotecan, Toripalimab	Phase 2	Recruiting	2024-07	China
Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma NCT06445088 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Observational	Recruiting	2024-05	China
TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma NCT06740370 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Anti-PD1 Antibody Drug: Lenvatinib	Not applicable	Recruiting	2024-12	China
Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients NCT07809893 · ClinicalTrials.gov ↗ · Colorectal Cancer Drugs: Celecoxib, Ivonescimab, MFOLFOXIRI	Phase 2	Recruiting	2026-08	China
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study) NCT06726421 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic	Phase 3	Recruiting	2024-09	China
Risk Assessment for HBV-Related Liver Cancer NCT07160946 · ClinicalTrials.gov ↗ · HBV-related Liver Cirrhosis	Observational	Recruiting	2025-05	China
Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) NCT05044117 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma Drug: Capecitabine	Phase 3	Recruiting	2021-10	China
Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma NCT07336979 · ClinicalTrials.gov ↗ · Resectable Mucosal Melanoma	Phase 2	Recruiting	2025-03	China
Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy NCT05468242 · ClinicalTrials.gov ↗ · Stage III Non-small Cell Lung Cancer Drugs: Bevacizumab, Tislelizumab	Phase 2	Recruiting	2022-01	China
Probiotics in Advanced Urothelial Carcinoma NCT06904573 · ClinicalTrials.gov ↗ · Advanced Urothelial Carcinoma, Probiotics, Immunotherapy Drugs: Cisplatin, Disitamab Vedotin, Enfortumab Vedotin	Phase 2	Recruiting	2025-01	China
TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer NCT06415318 · ClinicalTrials.gov ↗ · Penile Cancer Drugs: Ifosfamide, Paclitaxel	Phase 2	Recruiting	2024-05	China
Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma NCT06323382 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab	Observational	Recruiting	2021-01	China
Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma NCT04453813 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Chemotherapy, Radiotherapy Drug: Toripalimab	Phase 3	Recruiting	2020-07	China
Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid NCT07311772 · ClinicalTrials.gov ↗ · Nasopharyngeal Cancinoma (NPC), Radiation-induced Oral Mucositis	Phase 3	Recruiting	2025-12	China
The Value of Monitoring Circulating Cell DNA (ctDNA) in Pediatric Lymphoma: A Prospective, Multicenter Clinical Study NCT04957901 · ClinicalTrials.gov ↗ · Lymphoma	Observational	Recruiting	2021-12	China
Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients NCT03353467 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Endoscopic Surgery, Primary Napharyngeal Carcinama	Not applicable	Recruiting	2017-10	China
The Cold Ischemia Robot-assisted Partial Nephrectomy NCT07326280 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma, Renal Function Abnormal	Not applicable	Recruiting	2024-01	China
Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases NCT05768490 · ClinicalTrials.gov ↗ · Brain Metastases, Radiotherapy, EGFR Activating Mutation Drug: Almonertinib	Phase 3	Recruiting	2023-03	China
Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer NCT02966483 · ClinicalTrials.gov ↗ · Rectal Neoplasms Malignant, Surgery	Not applicable	Recruiting	2016-04	China
Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma NCT06587802 · ClinicalTrials.gov ↗ · Adrenocortical Carcinoma	Phase 2	Recruiting	2025-03	China
Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC NCT06197776 · ClinicalTrials.gov ↗ · Multi-omics Technique, Nasopharyngeal Carcinoma, Recurrent and Metastatic Nasopharyngeal Carcinoma	Observational	Recruiting	2024-07	China
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma NCT04453826 · ClinicalTrials.gov ↗ · Nasopharyngeal Cancer, Chemotherapy, Radiotherapy Drug: Camrelizumab	Phase 3	Recruiting	2020-09	China
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma NCT06323239 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma Drugs: Cisplatin, Gemcitabine, Toripalimab	Phase 2	Recruiting	2024-07	China
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma, Lymphoepithelial Carcinoma Drug: Becotatug Vedotin	Phase 1	Recruiting	2026-05	China
Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma NCT05949931 · ClinicalTrials.gov ↗ · Classic Hodgkin Lymphoma	Phase 2	Recruiting	2023-10	China
Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation NCT03671252 · ClinicalTrials.gov ↗ · Rectal Cancer Drugs: Folfoxiri, Xelox	Phase 3	Recruiting	2018-11	China
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC NCT06061276 · ClinicalTrials.gov ↗ · Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Drugs: Camrelizumab, Lenvatinib	Not applicable	Recruiting	2024-05	China
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response NCT06239727 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma Drugs: Capecitabine, Cisplatin, Gemcitabine	Phase 3	Recruiting	2024-03	China
Magnetic Tracking and ECG-Guided Tip Confirmation System for PICCs NCT07369427 · ClinicalTrials.gov ↗ · Peripherally Inserted Central Catheters	Observational	Recruiting	2026-01	China
Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma NCT07705243 · ClinicalTrials.gov ↗ · Nasopharyngeal Cancinoma (NPC) Drugs: Anti-PD1, Becotatug Vedotin	Phase 3	Recruiting	2026-07	China
QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma NCT06939855 · ClinicalTrials.gov ↗ · Bone and Soft Tissue Tumors	Phase 2	Recruiting	2025-09	China
Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition NCT04436965 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Nutrition Therapy Drug: Cisplatin	Phase 3	Recruiting	2021-08	China
Omitting CTV for Primary Tumor in LS-SCLC NCT07008716 · ClinicalTrials.gov ↗ · SCLC, Limited Stage, Radiation Exposure, Radiotherapy Side Effect Drugs: Carboplatin, Cisplatin, Etoposide	Phase 3	Recruiting	2025-06	China

Showing the 100 most recently updated of 490 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Sun Yat-sen University trials

161 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 121 more in the trial list above.

Conditions in Sun Yat-sen University trials

530 conditions

By trial register

Register	Trials	Recruiting
Clinical trials in China	490	250

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Nasopharyngeal Carcinoma

Sponsor	Trials
Zhejiang Cancer Hospital	4
XIANG YANQUN	3
Jiangxi Provincial Cancer Hospital	3
Zhongshan People's Hospital, Guangdong, China	3
Ming-Yuan Chen	3
Affiliated Cancer Hospital & Institute of Guangzhou Medical University	1

Sponsors with the most current trials registered for this condition.

Questions about Sun Yat-sen University trials

How many clinical trials does Sun Yat-sen University sponsor?

Sun Yat-sen University is the lead sponsor of 490 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Sun Yat-sen University trials recruiting?

Yes. 305 of its 490 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Sun Yat-sen University testing?

Its current trials name 161 drugs and biologicals as interventions. The most frequent are Cisplatin (29), Toripalimab (26), Gemcitabine (19), Sintilimab (17) and Bevacizumab (16). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Sun Yat-sen University clinical trials